Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of GVHD prophylaxis duration and post-transplant cyclophosphamide after allogeneic stem cell transplantation
NL-OMON47822Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Apr 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate sodium, cyclophosphamide and cyclosporine in graft-versus-host disease (GVHD), sponsored by HOVON. Started Apr 2010; status: active, not recruiting.
02
Drugs
mycophenolate sodiumcyclophosphamidecyclosporine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NL-OMON47822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47822.